Inozyme Pharma (INZY) Stock Statistics & Valuation Metrics

Inozyme Pharma has a market cap or net worth of $257.60M. The enterprise value is $100.04M.

Inozyme Pharma has 64,561,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inozyme Pharma’s return on equity (ROE) is -1.76 and return on invested capital (ROIC) is -99.36%.

The current PE Ratio of Inozyme Pharma is -1.71. Inozyme Pharma’s PEG ratio is 0.14.

In the last 12 months, Inozyme Pharma had revenue of 0.00 and earned -102.02M in profits. Earnings per share was -1.62.

In the last 12 months, operating cash flow was -91.91M and capital expenditures -62.00K, giving a free cash flow of -91.97M billion.

Inozyme Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Inozyme Pharma upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.

Inozyme Pharma as a current ratio of 3.56, with Debt / Equity ratio of 81.06%

In the past 12 months, Inozyme Pharma has paid 0.00 in taxes.

Inozyme Pharma EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -2.17.

Inozyme Pharma has $113.09M in cash and marketable securities with $46.87M in debt, giving a net cash position of -$66.21M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Inozyme Pharma is $7.89, which is 11.43% higher than the current price. The consensus rating is Moderate Buy